Shigellosis

This trial tests an experimental oral vaccine, WRSs2, designed to protect against Shigella sonnei, a common cause of severe diarrhea. Healthy adults aged 18-49 receive either the vaccine or a placebo, then are later exposed to the live bacteria in a controlled setting to see if t…

This study tested a new vaccine called Shigella4V2 to protect infants against shigellosis, a severe diarrheal disease. Researchers gave the vaccine to 110 healthy 9-month-old babies to check its safety and how well it triggers an immune response. The goal is to find the best dose…

This study tests a new vaccine called Shigella4V, designed to protect against shigellosis, a severe diarrheal disease. Researchers are giving the vaccine to healthy adults, children, and 9-month-old infants to check its safety and whether it triggers a strong immune response. Dif…

This study tested a new vaccine designed to protect against severe diarrhea caused by Shigella bacteria. The vaccine was first given to adults in Europe, then to adults, children, and infants in Africa. Researchers checked for side effects and measured immune responses to find th…

This early-stage study tested a new oral vaccine designed to protect against two bacteria that cause severe diarrhea: Shigella and ETEC. Fifty-three healthy adults received the vaccine to check for side effects and to see if it triggers an immune response. The goal is to develop …

This study tested a new Shigella vaccine in 200 healthy African infants to see if it can prevent severe diarrhea. The vaccine was given in two doses, and researchers measured immune responses and safety. The trial is now complete, and results will show whether this approach is pr…

This study tested a new vaccine called ShigETEC in healthy adults and children in Bangladesh. The vaccine aims to protect against two bacteria that cause severe diarrhea: Shigella and ETEC. Researchers gave three doses of the vaccine or a placebo to 196 participants to check if i…

This completed pilot trial tested two postbiotic supplements (ABB S3 and ABB C22) in 100 hospitalized patients with diarrhea or gut symptoms from tube feeding. The goal was to see if these nutritional supplements could ease symptoms like diarrhea, vomiting, and improve stool cons…